Adenovirus carrying HNF1α gene or shRNA against HNF1α gene was administrated into rats to access the effect of HNF1α on hepatic EPZ015666 clinical trial fibrogenesis in both dimethylnitrosamine and bile duct ligation models. The contribution of damaged hepatocytes in fibrogenesis was evaluated in rats with HNF1α knockdown and mice with hepatocyte-specific depletion of the SH2 domain-containing phosphatase-1 (SHP-1). Results: HNF1α expression was reduced in both human and rat fibrotic

livers. Inhibition of HNF1α in liver significantly aggravated hepatic fibrogenesis in two distinct rat fibrotic models. In contrast, forced expression of HNF1α markedly alleviated hepatic fibrosis in rats via transcriptional activation of SHP-1. HNF1α repression in hepatocytes initiated an inflammatory reaction that ultimately led to persistent hepatocellular damage via a feedback circuit consisting of HNF1α, SHP-1, STAT3, p65, miR-21 and miR-146a. This circuit also mediated a coordinated crosstalk between hepatocytes and hepatic stellate cells in vitro. HNF1α knockdown and conditional knockout of SHP-1 in hepatocytes induced hepatic fibrogenesis

in vivo. Conclusion: Our finding demonstrates that impaired hepatocytes play a critical role in hepatic fibrogenesis. Early intervention of HNF1α-regulated inflammatory feedback loop may have beneficial effects in the treatment of chronic liver BGJ398 datasheet diseases. Key Word(s): 1. Liver fibrosis; 2. HNF1α; 3. inflammation; 4. microRNA; Presenting Author: KUILIANG LIU Additional Authors: JING WU, XIANGCHUN LIN, CANGHAI WANG, HONG LIU, HUI SU, WENBIN SHEN Corresponding Author: JING WU Affiliations: Beijing Shijitan Hospital Objective: To summarize the clinical characteristics of chylous ascites in cirrhosis. Methods: Analyze retrospectively the clinical records of patients diagnosed as cirrhosis with chylous ascites in Gastroenterology Department and lymhatic surgery department of our hospital between January, Adenosine 2004 and November, 2012. Results: A total of 34 cases were included, accounting for 22.04% of cases of chylous

ascites in our hospital during the same period. The average age was 51.7 ± 12.5 years old. Hepatitis B is the most common cause (58.8%) of cirrhosis. The liver function varied between Child-Pugh B to C grade. Chylous test of ascites were all positive, with 16 cases (51.6%) had a chylous appearance. The SAAG level was 19.0 ± 7.62(2.6–32.5) g/L, and no less than 11 g/L in 27 cases (84.4%). The triglyceride level in ascites was 4.22 ± 4.16(0.26–16.75) mmol/L, and it was above 1.25 mmol/L in 27 cases (84.3%). The TG level in cases with a higher SAAG level (≥11 g/L) was significantly lower than cases with a lower SAAG level (<11 g/L) (3.46 ± 3.60 g/L vs 8.31 ± 4.97 g/L, p = 0.014). The radioactive tracer were detected leaking to peritoneal cavity during lymphoscintigraphy in 29 cases (85.3%). Direct lymphangiography revealed abnormality of lymphatic vessel structure in 16 cases (64%).